



INTELLECTUAL  
PROPERTY OFFICE  
BRUNEI DARUSSALAM

30 September 2023

NO. 009/2023



# PATENT JOURNAL

**Brunei Darussalam Intellectual Property Office (BruIPO)**

The Law Building, Ground Floor

Jalan Raja Isteri Pengiran Anak Saleha

Bandar Seri Begawan BA1910

Negara Brunei Darussalam

Tel: +673 2244873/4/5/6 Ext 102

Email: [enquiries@bruipo.gov.bn](mailto:enquiries@bruipo.gov.bn)

Brunei Darussalam Intellectual Property Office (BruIPO) © 2013. All rights reserved. Modification or reproduction of this Journal without the permission of BruIPO is prohibited.





## CONTENTS

General Information	3
Operating Hours	3
Submission of Application	3
Enquiries	3
Patents Legislation	4
Forms and Fees	4
INID Codes	5
First Schedule – Fees	7
Second Schedule – Forms	15
Third Schedule – Scale of Cost Part 1 – Basic Costs	19
Part II – Additional Cost	20
Fourth Schedule – Micro-Organisms	21
Fifth Schedule – Remuneration of Scientific Advisers	27
New Patent Applications Filed	34
Patent Renewal Application	41
Patent Granted	60
Patent Recordal of Change of Name	64

\*\*\*\*\*



## **General Information**

The Brunei Darussalam Intellectual Property Office (BruIPO) is an Office under the Attorney General's Chamber and its premises with effect from the 1 April, 2019 and is situated at the following address:

Brunei Darussalam Intellectual Property Office (BruIPO)  
Attorney General's Chamber  
The Law Building,  
Jalan Raja Isteri Pengiran Anak Hajah Saleha,  
Bandar Seri Begawan BA1910  
Brunei Darussalam  
Tel: +673 2225919

## **Opening Hours**

With effect from 1 January, 2020, the Brunei Intellectual Property Office (BruIPO) counter will operate as follows:

Monday to Thursday	: 8.00am to 12.00pm 2.00pm to 3.00pm
Saturday	: 8.00am to 11.00am
Friday and Sunday	: CLOSED

## **Submission of Applications**

1. All applications for the registration of patents must be lodged with the Registrar of Patents at the Brunei Darussalam Intellectual Property Office (BruIPO).
2. Submission of applications via fax is acceptable provided the documents transmitted are clear and legible (in particular, representations). For applications that require the payment of a fee, actual lodgement of the prescribed fee is required before such applications can be processed.

## **Enquiries**

1. For enquiries relating to any information in this Journal, kindly contact the Office at telephone numbers +673 2225919. Hard copies of the Journal can be purchased upon request from the Office at a cost of B\$10.00 per copy.
2. The website of the Brunei Darussalam Intellectual Property Office (BruIPO) is <http://www.bruipo.gov.bn>.
3. All Patent-related enquiries via email can be submitted to [enquiries@bruipo.gov.bn](mailto:enquiries@bruipo.gov.bn)

\*\*\*\*\*



## **Patents Legislation**

1. The legislation governing the registration of Patent in Brunei Darussalam is the Patents Order 2011, while the subsidiary legislation is the Patents Rule, 2012.
2. The hard copies of the legislation can be purchased from: Print Plus Sdn Bhd Prime Minister's Office Jalan Airport Lama Bandar Seri Begawan BB3510 Brunei Darussalam Tel: 238 2541
3. The soft copies of the legislation can be obtained from [www.bruipo.gov.bn](http://www.bruipo.gov.bn)

## **Forms and Fees**

1. For any proceedings before the Registry, the prescribed form to be used and the accompanying fee payable shall be in accordance with the First and Second Schedule of the Patents Rule, 2012.
2. Payment by cheque should be made out to 'THE GOVERNMENT OF BRUNEI DARUSSALAM'.

## **Restrictions on Applications Abroad by Residents of Brunei Darussalam**

1. Local applicants intending to file a patent abroad must first obtain the Registrar's written authority as prescribed under section 33(1) of the Patents Order, 2011.
2. Failure to observe this requirement is an offence under section 33(1)(b)(3) of the Order.

## **Transitional Applications**

1. Transitional applications under Section 115 shall be lodged with the Registrar of Patents in the following manner:
  - Request to the Registrar of Patents for re-registration of a Singapore, Malaysia or United Kingdom/European patent;
  - Lodgement of Patent Form PF46;
  - Certified true copy of the grant of patent in the relevant country;
  - Prescribed fee of B\$250.00; and
  - Any other supporting documents that the Registrar deems necessary.
2. The filing of a Power of Attorney accompanying a request for re-registration is no longer a requirement with effect from 1 January 2012.



3. Any renewal due for patents registered under the repealed Inventions Act (Cap 72) on or after 1 January 2012 shall be made in accordance with Section 54 on Patents Form PF20. Applicants must furnish supporting documents proving the validity of the patents which are due for renewal.

4. Search on the Register of patents (re-registrations) can be conducted at the Office by completing a Search Form PF30 and the payment of a search fee of \$6.50 per hour.

\*\*\*\*\*



## **'INID' NUMBERS IN USE ON BRUNEI PATENT DOCUMENTS**

'INID' is an acronym for Internationally agreed Numbers for the Identification of Data'

(10) Document identification

- (11) Number of the document
- (12) Plain language designation of the kind of document
- (19) WIPO country code, or other identification, of the country publishing the document.

(20) Document filing data

- (21) Number(s) assigned to the application(s)
- (22) Date(s) of filing application(s)
- (23) Other date(s) of filing, including exhibition filing date and date of filing complete specification following provisional specification.
- (24) Date from which industrial property rights may have effect.

(30) Priority data

- (31) Number(s) assigned to priority application(s).
- (32) Date(s) of filing priority application(s).
- (33) Country (countries) in which the priority application(s) was (were) filed.

(40) Date(s) of making available to the public

- (43) Date of publication by printing or similar process of unexamined document, on which no grant has taken place on or before the said date.
- (44) Date of publication by printing or similar process of an examined document, on which no grant has taken place on or before the said date.
- (45) Date of publication by printing or similar process of a document, on which grant has taken place on or before the said date.
- (47) Date of making a granted patent available to the public by viewing, or copying on request

(50) Technical information

- (51) International Patent Classification
- (52) Domestic or national classification
- (54) Title of invention
- (56) List of prior art documents, if separate from descriptive text.
- (57) Abstract or claim.

(60) Reference(s) to other legally related domestic document(s)

- (60) Related by cognate(s).
- (61) Related by addition(s).
- (62) Related by division(s).

(70) Identification of parties concerned with the document



- (70) Name(s) of nominated person
- (71) Name(s) of applicant(s).
- (72) Name(s) of inventor(s) if known to be such.
- (74) Name(s) of attorney(s) or agent(s).
- (75) Name(s) of inventor(s) who is (are) also applicant(s)

(80) Identification of data related to International Conventions other than the Paris Convention

- (86) PCT Application Number.
- (87) PCT Publication Number.

**NOTE**

- (1) The classification used is the International Patent Classification and is identified by the INID code (51). Further editions of the classification are identified as (51)2, (51)3, (51)4 and (51)5.
- (2) INID code 74 provides for the name of patent attorney, or firm of attorneys, prosecuting an application.

\*\*\*\*\*



## **PRACTICE NOTE 2012/01**

### **PATENT RENEWALS**

#### **• RENEWAL OF PATENTS REGISTERED UNDER SECTION 115 OF THE PATENTS ORDER**

1. For Section 115 applications, the following original documents need to be signed and submitted to the Registry of Patents:

- (a) PF20;
- (b) PF46 (for the first instance of renewal payment if that agent is not previously appointed);
- (c) evidence of the original patent not having been revoked, and
- (d) a cheque drawn on a Brunei bank account including the correct fee for both the PF20 and PF46. Cheques must be made payable to 'THE GOVERNMENT OF BRUNEI DARUSSALAM'.

#### **2. PF20**

The notes at the top of the form and applicable provisions in the Patents Order and Patent Rules should be followed strictly. Additional formatting guidelines are as follows:

Section 2: Brunei registration number in format RP/XX/YYYY for pre 2012 cases, and RE YYYY/XXXX for 2012 onwards.

Section 3: Original Patent number in the format UK: GBXXXXXXX or EPXXXXXXX; MY: MY-XXXXXX-A; and SG: XXXXX.

Section 4: This should match the current details on the Brunei Register (rather than the original patent register details).

Section 5: Agents attending to the renewal on behalf of the proprietor should leave Section 5 blank and instead fill in details in Section 7 and 8.

Section 6: The renewal deadline is calculated from the date of filing for all UK, MY and SG original cases.

#### **3. PF46**

Section 6: Most commonly the appointment is for renewal matters only, so the "for renewals only" box should be checked, assuming the agent has not been previously appointed.

#### **4. PF21**

Extension fees will become payable for renewals as of 1 January 2013.

#### **5. Certification of original patent**

Evidence must be provided that the original patent must not be "revoked" as of the date of the renewal being paid. Please note it does not matter if the original patent has "lapsed" or "ceased". Evidence can be in the form of a certified true copy of the applicable online register printed on the day of filing or a



statutory declaration to the same effect. The online register of the original patent can be printed and certified as a true copy by the authorised agent for the renewal using a suitable chop and signature.

- **EXPIRY OF PATENT AT THE END OF THE TERM OF THE PATENT**

6. Agents are reminded that under Section 115(4)(a), the term of a Section 115 patent is 20 years from the date of filing of the original (UK/MY/SG) patent; subject to Section 35 and 36. It does not make any difference which country the original patent is from.

### **AMENDMENT OF RULE 92 OF S 19/2012**

Rule 92 of the Patent Rules, 2012, is amended by repealing sub-rule (1) and by substituting the following new sub-rule therefor –

“(1) Subject to this rule, in relation to an international application for a patent (Brunei Darussalam) which is, under section 82, to be treated as an application for a patent under the Order, the prescribed period for the purpose of section 83(3) and (5) shall be, in a case where Brunei Darussalam has been designated and/or elected in accordance with the Patent Co-operation Treaty, 30 months from the relevant date.”.

### **AMENDMENTS AND CORRECTIONS**

- **AMENDMENT OF SPECIFICATION (RULES 51) OR CORRECTION OF ERROR IN SPECIFICATION (RULE 64)**


1. Unless required by the Registry under rules 51, an application for amendment of specification or a request for correction of an error in proposed amendment/correction incorporated; only a copy of the specification with the amendment/ correction indicated clearly therein is required. If a copy of the specification with the proposed amendment/correction incorporated is nonetheless filed, please be informed that the Registry will not review that document or consider it in any proceedings before the Registry.
2. The registry would also like to point out the replacement sheets with clear markings will reduce the need for clarification or further correspondences and hence will help expedite the processing of such requests.

- **AMENDMENTS/CORRECTIONS TO SPECIFICATION AND ABSTRACT**


1. Amendments/corrections to patent specifications and abstracts are to be clearly marked and completed by striking through text/figure etc. to be replaced, and by underlining replacement text/figure etc.
2. The following 3 examples reflect 3 possible alternative ways to which the changes could be represented. Example 4 reflects a situation where Patents Form 19 is filed.



**Example 1: Page 10 of 19 sheets (Specification) is amended**




**Example 2: Page 10 of 19 sheets (Specification) is amended**






### Example 3: Page 10 of 19 sheets (Specification) is amended



This vertical line indicates the matter replacing the whole of page 10. To facilitate the document reproduction process however, the line should be placed about 0.5 cm to 1cm away from the 2.5 cm margin of each sheet.

### Example 4: Page 10 of 19 sheets (Specification) is amended





- **COMMONLY MADE MISTAKES WHEN FILING PATENTS FORM 17**

The following are some of the commonly made mistakes in relation to making a request for amendments –

- Replacement sheets for amendments are not filed with Patents Form 17. –
- There is no marked up copy enclosed with Patents Form 17. –
- Patents Form 17 is filed without any replacement sheet. -
- Amendments to be made given on Patents Form 17 are different from the replacement sheets.

### **REGISTRATION UNDER SECTION 115**

The following applications were processed through the Registry of Patents under section 115 of the Patents Order, 2011. Application numbers beginning with 'RP' are applications which were filed under the repealed Inventions Act (Cap 72) and were pending on 1 January 2012. Application numbers beginning with 'RE' are new re-registration applications filed after the implementation of the new Patents Order, 2011.

---

Date of filing:	17 February, 2020
Application No.:	RE/R/2020/0001
Patent No.:	EP2580236 B1 and US352461 P
Date of Grant:	8 June, 2011
Applicant (s)/Proprietor(s):	ASTRAZENECA AB and PIERIS PHARMACEUTICALS GMBH
Title:	TEAR LIPOCALIN MUTEINS BINDING IL-4 R ALPHA

\*\*\*\*\*



## FIRST SCHEDULE

### FEES PAYABLE

<u>Matter</u>	<u>Fee</u>	<u>Corresponding Form(s)</u>
1. On filing a request for the grant of a patent	\$160.00	1
2. On reference under section 20(1) or 48(1)	\$450.00	2
3. On filing a counter-statement in each of the following cases –	\$40.00	3
(a) Opposing the making of an order under section 20 or 48		
(b) Opposing a request under section 22		
(c) In respect of a reference under section 23(5)		
(d) Opposing an application under section 24		
(e) In answer to a notice of opposition under section 38		
(f) In answer to a notice of opposition under section 41		
(g) In respect of a reference under section 49(5)		
(h) In respect of an application under section 55(3)		
(i) In answer to a notice of opposition under section 56(7)		
(j) In respect of a reference under section 65(3)		
(k) On contesting an application under section 76 for declaration of non- infringement		
(l) On contesting an application under section 77 for revocation of a patent		
(m) In answer to a notice of opposition under section 104(2) to the correction of an error, clerical error or mistake		
4. On application under section 20(5) or 48(3) for authorization by Registrar	\$50.00	4
5. On request for directions under section 22	\$450.00	5

6. On reference under section 23(5) or 49(5) to determine the question of licence	\$450.00	6
7. On application to the Registrar under section 24(1) 450 7 and/or 24(3)	\$450.00	7
8. On filing a statement of inventorship and of right to the grant of a patent	-	8
9. On request for early publication under section 27(2)	\$50.00	9
10. On filing a notice of withdrawal of an application for a patent under section 27(1)	-	10
11. On filing a request for a search report or a supplementary search report	\$1750.00	11
12. On filing a request for a search and examination report	\$2600.00	12
13. On furnishing information referred to in rule 46(1)	-	14
14. On filing a notice of intention to rely on an international preliminary report on patentability	-	15
15. On filing a request for an examination report	\$1100.00	16
16. On request to amend application before grant	-	17
17. On filing a response to a written opinion under section 31 or 39	-	18
18. On request that a certificate of grant be issued –		19
(a) where the application for a patent has not more than 25 claims in the patent specification when rule 49(3) is complied with	\$200.00	
(b) where the application for a patent has more than 25 claims in the patent specification when rule 49(3) is complied with	\$200.00 plus \$20.00 for Each claim in excess of 25 claims	
19. On payment of renewal fee (not including payment of back renewal fees pursuant to restoration or cancellation of entry in the register that licences are available as of right)	-	20

(a) for each year in respect of the 5th, 6th or 7th year of the patent		
(b) for each year in respect of the 8th, 9th or 10th year of the patent	\$160.00	
(c) for each year in respect of the 11th, 12th or 13th year of the patent	\$270.00	
(d) for each year in respect of the 14th, 15th or 16th year of the patent	\$350.00	
(e) for each year in respect of the 17th, 18th or 19th year of the patent	\$450.00	
(f) for the 20th year of the patent	\$550.00	
(g) for each year after the 20th year of the patent	\$650.00	
	\$950.00	
20. On payment of an additional fee for renewal under section 35(3) –		21
(a) not exceeding one month	\$50.00	
(b) each succeeding month (but not exceeding 6 months)	\$100.00	
21. On application to amend specification after grant	\$100.00	22
22. On notice of opposition to amendment of specification after grant	\$480.00	23
23. On application for the restoration of a patent	\$500.00	24
24. On payment of additional fee on the application for the restoration of a patent	\$300.00	25
25. On filing an offer to surrender a patent	\$70.00	26
26. On notice of opposition to offer to surrender a patent	\$250.00	27
27. On application to register or give notice of a transaction, instrument or event affecting the rights in a patent or an application for a patent – for each patent or application for a patent affected by such transaction, instrument or event	\$70.00	29
28. On filing a request, in respect of one or more patents or applications for patents, for –	\$12.00	28
(a) each alteration or correction of name		



(b) each alteration or correction of address (not being an address for service)		
29. On filing a request, in respect of each patent or application for a patent, for –	\$12.00	28
(a) each alteration or correction of address for service		
(b) each correction of an error in the register or any connected document		
(c) each correction of an error of translation or transcript or clerical error or mistake in the specification of a patent, in an application for a patent or in any document filed in connection with a patent or such an application		
30. On request for the furnishing of or access to miscellaneous information –		30
(a) fee for inspecting each file or document relating to a patent or patent application	\$6.50	
(b) fee for furnishing each file or document	\$6.00	
(c) fee for photocopying each page or part thereof of any other document by the staff of the Registry	\$0.30	
(d) where the document is placed in the public search room –		
(i) fee for self-service photocopying of each page or part of the document using a stored-value card	\$0.15	
(ii) fee for photocopying of each page or part thereof by the staff of the Registry	\$0.30	
31. On request for certificate of the Registrar –		31
(a) by impressed stamp -		
(i) for the first 20 sheets	\$18.00	
(ii) for each additional sheet thereafter	\$0.30	
(b) sealed and attached to the documents -		
(i) for the first 20 sheets	\$30.00	

(ii) for each additional sheet thereafter	\$0.30	
(c) in respect of a priority document under rule 17.1(b) of the Regulations under the Patent Cooperation Treaty	\$50.00	
(d) in respect of a certified copy of the international application for a patent under rule 124	\$28.00	
32. On application for entry of order of court in the register	\$10.00	32
33. On application by proprietor for entry to be made in the register to the effect that licences under the patent are to be available as of right	\$70.00	33
34. On application for settlement of terms of licence of right	\$380.00	34
35. On application under section 56(1) or section 56(3) for cancellation of entry in the register	\$70.00	35
36. On notice of opposition to an application under section 56(1) or 56(3) for cancellation of entry in the register	\$90.00	36
37. On reference to the Registrar of a dispute as to infringement	\$280.00	37
38. On application for declaration of non- infringement	\$280.00	38
39. On application under section 77 for the revocation of a patent	\$500.00	40
40. On request for re-examination of a patent in response to the Registrar's direction	\$900.00	41
41. On request for re-examination of a patent in response to the Registrar's direction	\$160.00	42
42. On payment of prescribed fee and request for publication of translation	\$70.00	43
43. On application to Registrar for an international application for a patent (Brunei Darussalam) to be treated as an application under the Order	\$160.00	44
44. On request for the exercise of the discretionary powers of the Registrar	\$100.00	48

45. On declaration of authorisation where agent appointed or in substitution for another	\$10.00 for each patent or application for patent	46
46. On payment of the advertisement fee upon receipt of the Registrar's request under rule 97(4)	\$18.00	47
47. On notice of opposition to the correction of an error, clerical error or mistake	\$100.00	48
48. On request for information relating to a patent or an application for a patent	\$24.00	49
49. On request for extension of each time or period under rule 114(4) - for each month or part of a month for which the extension is sought	\$200.00	50
50. On request for extension of each time or period under rule 114(6)	\$200.00	52
51. On payment of additional fee for extension of each time or period under rule 114(9) – for each month, or part of a month, for which the extension is granted	\$200.00	53
52. On request for extension of periods under sections 51 29(7) and 30(1)(a) –  (a) where the application is not an international application for a patent (Brunel Darussalam) that has entered the national phase in Brunei Darussalam under section 83(3)	\$1800.00	
(b) where the application is an international application for patent (Brunei Darussalam) that has entered the national phase in Brunei Darussalam under section 83(3)	Nil	
53. On payment of transmittal fee under rule 14 of the Regulations under the Patent Co-operation Treaty	\$150.00	54
54. On payment of fee under rule 123(6) in respect of a request under rule 26 bis.3(a) of the Regulations under the Patent Co-operation Treaty	\$250.00	-

55. On request for certificate authorising release of sample of micro-organism	\$15.00	55
56. On notice of intention to restrict availability of samples of micro-organisms to experts	\$15.00	56
57. On request for certificate authorising release of sample of micro-organism to an expert	\$15.00	57
58. On payment of renewal fee under section 55 or 56 –		58
(a) for each year in respect of the 5th, 6th or 7th year of the patent	\$80.00	
(b) for each year in respect of the 8th, 9th or 10th year of the patent	\$135.00	
(c) for each year in respect of the 11th, 12th or 13th year of the patent	\$175.00	
(d) for each year in respect of the 14th, 15th or 16th year of the patent	\$225.00	
(e) for each year in respect of the 17th, 18th or 19th year of the patent	\$275.00	
(f) for the 20th year of the patent	\$325.00	
(g) for each year after the 20th year of the patent	\$475.00	
59. On application to extend the term of a patent under section 36	\$950.00	59
60. On filing a request for a search and examination report 60 after grant under section 39 –		60
(a) where the Examiner is the Austrian Patent Office	\$2680.00	
(b) where the Examiner is the Danish Patent and Trademark Office	\$3100.00	
(c) where the Examiner is the Hungarian Patent Office	\$2680.00	
61. On filing one or more documents under section 26(7)(c) or (8) or 28(8)	-	61

62. On filing a declaration under rule 9(2) or a request under rule 9(3)	\$120.00	62
63. On filing a request under rule 10(2)	\$250.00	62
64. On filing any miscellaneous document or documents	-	99
65. For using the patent computer facilities in the public search room of the Registry		
(a) for every half hour or part thereof of log on 2 access using the patent search terminal	\$2.00	
(b) for each sheet of information printed	\$0.30	
66. Purchase of a copy of —		
(a) Patents Journal A	\$10.00	
(b) Patents Journal B	\$36.00	

\*\*\*\*\*



## SECOND SCHEDULE

### DESCRIPTIONS OF FORMS

<u>No.</u>	<u>Description of Form</u>	<u>Corresponding Form No.</u>
1	Certificate of Grant	Certificate Form 1
2	Certificate of Extension of Patent Term	Certificate Form 2
3	Request for the Grant of a Patent under section 25	Patents Form 1
4	Reference under section 20(1) or 48(1)	Patents Form 2
5	Counter statement	Patents Form 3
6	Application under section 20(5) or 48(3) for Authorisation by the Registrar	Patents Form 4
7	Request for Directions under section 22	Patents Form 5
8	Reference under section 23(5) or 48(5) to Determine the Question of a Licence	Patents Form 6
9	Application to Registrar under section 24(1) and/or 24(3)	Patents Form 7
10	Statement of Inventorship and of Right to the Grant of a Patent under section 24	Patents Form 8
11	Request for Early Publication under section 27(2)	Patents Form 9
12	Withdrawal of an Application for a Patent under section 27(1)	Patents Form 10
13	Request for a Search Report or Supplementary Search Report	Patents Form 11
14	Request for a Search and Examination Report	Patents Form 12
15	Furnishing of Prescribed Details	Patents Form 13
16	Furnishing of Prescribed Information	Patents Form 14
17	Notice of Intention to Rely on International Preliminary Report on Patentability under section 29(2)(e)(ii)	Patents Form 15
18	Request for an Examination Report	Patents Form 16
19	Request to Amend Application before Grant under section 31(2)	Patents Form 17



20	Response to Written Opinion under section 31 or 39	Patents Form 18
21	Payment of Fee for Grant of a Patent under section 30	Patents Form 19
22	Payment of Renewal Fee under section 35(2) or 56(2)	Patents Form 20
23	Payment of Additional Fee under section 35(3)	Patents Form 21
24	Application to Amend Specification after Grant under section 38	Patents Form 22
25	Notice of Opposition to Amendment of Specification after Grant under section 38 or 80	Patents Form 23
26	Application for Restoration of a Patent under section 40	Patents Form 24
27	Additional Fee on the Application for Restoration of a Patent under section 40	Patents Form 25
28	Offer to Surrender a Patent under section 41(1)	Patents Form 26
29	Notice of Opposition to Offer to Surrender a Patent under section 41(2)	Patents Form 27
30	Request for Alteration of Name, Address or Address for Service, or Correction of an Error, Clerical Error or Mistake under section 104	Patents Form 28
31	Application to Register or to Give Notice of a Transaction, Instrument or Event Affecting the Rights in a Patent or an Application for a Patent under section 44	Patents Form 29
32	Request for Miscellaneous Information under section 43 or 105	Patents Form 30
33	Request for Certificate of the Registrar under section 46	Patents Form 31
34	Application for Entry of Order of Court in the Register under section 44	Patents Form 32
35	Application for Entry to be Made in the Register to the effect that Licences under the Patent are to be available as of Right under section 55(1)	Patents Form 33
36	Application for Settlement of Terms of a Licence of Right under section 55(3)	Patents Form 34
37	Application under section 56(1) or (3) for Cancellation of Entry in the Register	Patents Form 35
38	Notice of Opposition to an Application under section 56(1) or (3) for Cancellation of Entry in the Register	Patents Form 36



39	Reference to the Registrar of a Dispute as to Infringement under section 65(3)	Patents Form 37
40	Application for Declaration of Non-Infringement under section 76	Patents Form 38
41	Application for Information on Corresponding Applications for a Patent	Patents Form 39
42	Application for Revocation of a Patent under section 77	Patents Form 40
43	Request for Re-Examination of a Patent in Response to direction of the Registrar under section 77	Patents Form 41
44	Payment of Fee for Entry into National Phase under section 83(3)	Patents Form 42
45	Payment of Prescribed Fee and Request for Publication of Translation under section 83(7)	Patents Form 43
46	Application to the Registrar for an International Application to be Treated as an Application under section 82 of the Order	Patents Form 44
47	Request for the Exercise of the Registrar's Discretionary Powers under section 89	Patents Form 45
48	Declaration of Authorisation where an Agent is Appointed or where One Agent is Substituted for Another	Patents Form 46
49	Additional Fee for the Advertisement of Proposed Correction under section 104	Patents Form 47
50	Notice of Opposition to the Correction of an Error, Clerical Error or Mistake under section 104	Patents Form 48
51	Request for Information Relating to a Patent or an Application for a Patent under section 105	Patents Form 49
52	Request for Extension of Time or Period under rule 114(4)	Patents Form 50
53	Request for Extension of Periods under sections 29 (7) and 30(1)(a)	Patents Form 51
54	Request for Extension of Time or Period under rule 114(6)	Patents Form 52
55	Additional Fee for Extension of Time or Period under rule 114(9)	Patents Form 53



56	Payment of Transmittal Fee under rule 14 of the Regulations under the Patent Co-Operation Treaty	Patents Form 54
57	Request for Certificate Authorising Release of Sample of Micro-Organism	Patents Form 55
58	Notice of Intention to Restrict Availability of Samples of Micro-Organisms to Experts	Patents Form 56
59	Request for Certificate Authorising Release of Sample of Micro-Organisms to an Expert	Patents Form 57
60	Payment of Renewal Fee pursuant to section 55(3)(d)	Patents Form 58
61	Request for an Extension of the Term of a Patent under section 36	Patents Form 59
62	Request for Search and Examination after Grant under section 39	Patents Form 60
63	Filing of Documents under section 26(7)(c) or (8) or 28(8)	Patents Form 61
64	Declaration under rule 9(2) or Request under rule 9(3) or 10(2)	Patents Form 62
65	Filing of Miscellaneous Document or Documents	Patents Form 99

\*\*\*\*\*



## **THIRD SCHEDULE**

### **SCALE OF COSTS**

#### **PART I**

##### **BASIC COST**

<i>Item</i>	<i>Matter</i>	<i>Amount</i>
1	Drawing and filing notice of opposition or application for revocation together with statement of case	\$200.00
2	Drawing and filing a counter-statement	\$150.00
3	Preparing and lodging evidence for a notice of opposition, an application for revocation or a counter-statement	\$200.00 - \$800.00
4	Perusing a notice of opposition, an application for revocation or a counter-statement (per folio)	\$2.00 per folio
5	Preparing for all interlocutory proceedings	\$25.00 - \$120.00
6	Attending all interlocutory proceedings	\$25.00 - \$50.00
7	Preparing for hearing	\$500.00 - \$1500.00
8	Attendance at hearing by patent agent without advocate or solicitor	\$100.00 per hour up to a maximum of \$450.00 per day
9	Attendance at hearing by patent agent with instructing advocate or solicitor	\$60.00 per hour up to a maximum of \$270.00 per day
10	Advocate or Solicitor fees	\$120.00 per hour up to a maximum of \$540.00 per day
11	Drawing bill of costs (per folio)	\$2.00 per folio
12	Attending taxation, and obtaining the Registrar's certificate or order	\$50.00 - \$120.00

\*\*\*\*\*



## **PART II**

### **ADDITIONAL COSTS**

1. A person who has paid a fee prescribed in these Rules in relation to proceedings before the Registrar shall be paid the amount of the fee.
2. A person attending proceedings before the Registrar shall be paid –
  - (a) a reasonable amount for expenses incurred for transport between the usual place of residence of the person and the place that he attends for that purpose; and
  - (b) if the person is required to be absent overnight from his usual place of residence, a reasonable amount as allowances up to a daily maximum of \$250 for meals and accommodation.
3. A person who, because of his professional, scientific or other special skill or knowledge, is summoned to appear before the Registrar as a witness shall be paid –
  - (a) if the person is remunerated in his occupation by wages, salary or fees, an amount equal to the amount of wages, salary or fees not paid to the person because of his attendance before the Registrar for that purpose, but such amount should not exceed \$150 per day; or
  - (b) in any other case, an amount of not less than \$100 but not more than \$150 for each day on which he so attends.

\*\*\*\*\*



## **FOURTH SCHEDULE**

### **MICRO-ORGANISMS**

#### **Applications.**

1. (1) The specification of an application for a patent, or of a patent, for an invention which requires for its performance the use of a micro-organism –

- (a) which is not available to the public at the date of filing of the application; and
- (b) which cannot be described in the specification in such a manner as to enable the invention to be performed by a person skilled in the art, shall, in relation to the micro-organism itself, be treated for the purposes of the Order as disclosing the invention in such a manner only if one of the conditions set out in subparagraph (2), is satisfied.

(2) The conditions referred to in sub-paragraph (1) are –

- (a) a condition that –
  - (i) not later than the date of filing of the application, a culture of the micro-organism has been deposited with any international depositary authority which is able to furnish a sample of the micro-organism; and
  - (ii) the name of the international depositary authority, the date when the culture was deposited and the accession number of the deposit are given in the specification of the application; and
- (b) a condition, in the case of an international application for a patent (Brunei Darussalam) which is treated, by virtue of section 85 as a patent under the Order, or, as the case may be, an application for a patent under the Order, that the corresponding provisions of the Implementing Regulations to the Patent Co-operation Treaty have been complied with, and where a new deposit is made under paragraph 4, a further condition that the applicant or proprietor makes a new deposit in accordance with that paragraph.

(3) Where the condition of sub-paragraph (2)(a)(ii) is not satisfied at the time the application for a patent is filed, it shall be satisfied –

- (a) within 16 months from –
  - (i) the declared priority date; or
  - (ii) the date of filing the application where there is no declared priority date;
- (b) where, on a request made by the applicant, the Registrar publishes the application before the end of the period prescribed for the purposes of section 27(1), before the



date of the request; or

- (c) where the Registrar sends notification to the applicant that, in accordance with section 105(4), he has received a request by any person for information and inspection of documents under subsection (1) of that section, before the end of one month after his sending to the applicant notification of his receipt of the request, whichever is the earliest.
- (4) The giving of the information specified in sub-paragraph (2)(a)(ii) shall constitute the unreserved and irrecoverable consent of the applicant to the international depositary authority with which a culture (including a deposit which is to be treated as having always been available by virtue of paragraph 4(2)) is from time to time deposited making the culture available on receipt of the Registrar's certificate authorising the release to the person who is named therein as a person to whom the culture may be made available and who makes a valid request therefor to the authority.

### **Availability of cultures.**

- 2. (1) Subject to paragraph 3, a request that the Registrar certify a person as a person to whom an international depositary authority may furnish a sample of a micro-organism –
  - (a) before publication of the application for a patent, to a person who has made a request under section 105(1) in the circumstances mentioned in paragraph 1(3)(c); and
  - (b) at any later time, to any person, shall be made on Patents Form 55 together with the form provided for by the Regulations under the Budapest Treaty.
- (2) The Registrar shall send a copy of any form lodged with him under subparagraph (1) and of his certificate authorising the release of the sample –
  - (a) to the applicant for, or proprietor of, the patent;
  - (b) to the international depositary authority; and (c) to the person making the request.
- (3) A request under sub-paragraph (1) shall comprise, on the part of the person to whom the request relates, undertakings for the benefit of the applicant for, or proprietor of, the patent –
  - (a) not to make the culture, or any culture derived from it, available to any other person; and
  - (b) not to use the culture, or any culture derived from it, otherwise than for experimental purposes relating to the subject matter of the invention, and –
    - (i) subject to sub-paragraph (iii), both undertakings shall have effect during any period before the application for a patent has been withdrawn, has been treated as having been abandoned, has been refused or is treated as having been refused (including any further period allowed under rule 110, 120(1) or (6) but excluding,



where an application is reinstated under either of those rules, the period before it is reinstated);

- (ii) if a patent is granted on the application, the undertaking set out in sub-paragraph (a) shall also have effect during any period for which the patent is in force and during the period of 6 months referred to in section 35(3); and
- (iii) the undertaking set out in sub-paragraph (b) shall not have effect after the date of publication in the journal of a notice that the patent has been granted, and, in this sub-paragraph, references to a culture derived from a deposited culture of a microorganism are references to a culture so derived which exhibits those characteristics of the deposited culture essential for the performance of the invention.

(4) For the purpose of enabling any act specified in section 59 to be done in relation to the culture for the services of the Government, the undertakings specified in subparagraph (3) –

- (a) shall not be required from any Government department or person authorised in writing by a Government department for the purposes of this paragraph; and
- (b) shall not have effect in relation to any such person who has already given them.

(5) An undertaking given pursuant to sub-paragraph (3) may be varied by way of derogation by agreement between the applicant or proprietor and the person by whom it is given.

(6) Where, in respect of a patent to which the undertaking set out in sub-paragraph (3)(a) has effect –

- (a) an entry is made in the register under section 55 to the effect that licences are to be available as of right; or
- (b) a compulsory licence is granted under section 57, that undertaking shall not have effect to the extent necessary for effect to be given to any such licence.

### **Availability of cultures to experts.**

3. (1) Subject to sub-paragraph (3), where, before the preparations for publication under section 27 of an application for a patent have been completed, the applicant gives notice to the Registrar on Patents Form 56 of his intention that a sample of the microorganism should be made available only to an expert, the provisions of this paragraph shall have effect.

(2) The Registrar –

- (a) shall, at the time of publication of the application under section 27, publish a notice in the journal that the provisions of this paragraph have effect; and
- (b) notwithstanding paragraph 2, shall not, until the patent is granted or the application has been withdrawn, has been treated as having been abandoned, has been refused or is



treated as having been refused, issue any certificate authorising release of a sample otherwise than under this paragraph.

(3) In the case of an international application for a patent (Brunei Darussalam), the applicant may, for the purpose set out in sub-paragraph (1), give notice in writing to the International Bureau under rule 13 bis 3 of the Regulations under the Patent Co-operation Treaty before the technical preparations for international publication of the application are complete of his intention that a sample of the micro-organism should be made available only to an expert and he shall be treated by the Registrar for the purposes of this paragraph as having complied with the conditions in sub-paragraph (1) and sub-paragraph (2)(a) shall not apply.

(4) Any person wishing to have a sample of the micro-organism made available ("the requester") –

(a) shall apply to the Registrar on Patents Form 57 together with the form provided for by the Regulations under the Patent Co-operation Treaty nominating the person ("the expert") to whom he wishes the sample to be made available; and

(b) shall at the same time file undertakings by the expert as set out in paragraph 2 (3) in accordance with the provisions of that paragraph.

(5) The Registrar shall send a copy of Patents Form 57 filed under sub-paragraph (4) to the applicant for the patent and shall specify the period within which the applicant may object, in accordance with sub-paragraph (6), to a sample of the micro-organism being available to the expert.

(6) Unless, within the period specified by the Registrar under sub-paragraph (5) (or within such longer period as the Registrar may, on application made to him within that period, allow), the applicant for the patent sends notice in writing to the Registrar that he objects to a sample of the micro-organism being made available to the expert and gives his reasons for his objection, the Registrar shall send a copy of any form lodged with him under sub-paragraph (4)(a) and of his certificate authorising the release of the sample –

(a) to the applicant for the patent;  
(b) to the international depositary authority concerned;  
(c) to the requester; and  
(d) to the expert.

(7) Where, in accordance with sub-paragraph (6), the applicant for the patent sends notice to the Registrar of his objection to the issue of a certificate in favour of the expert, the Registrar –

(a) shall decide, having regard to the knowledge, experience and technical qualifications of the expert and to any other factors he considers relevant, whether to issue his certificate in favour of the expert; and

(b) if he decides to authorise the release of the sample to the expert, shall send to the persons



referred to in sub-paragraph (6) a copy of any form lodged with him under subparagraph (4)(a) and of his certificate authorising the release of the sample to the expert.

(8) Before making a decision in accordance with sub-paragraph (7), the Registrar shall afford the applicant and the requester the opportunity of being heard.

(9) If the Registrar decides under sub-paragraph (7) not to issue his certificate in favour of the expert, the requester may, by notice in writing to the Registrar and the applicant, nominate another person as the expert for the purposes of this paragraph; and the Registrar shall give such directions as he may think fit with regard to the subsequent procedure.

(10) Nothing in this paragraph shall affect the rights under section 58 of any Government department or of any person authorised in writing by a Government department.

### **New deposits.**

4. (1) Where the international depositary authority with which a deposit or a new deposit of a culture has been made under this Schedule –

(a) notifies the applicant or proprietor that it –

(i) cannot satisfy a request made in accordance with paragraph 2(1) or 3(4); or

(ii) is not able lawfully, to satisfy such a request, for the culture to be made available;

(b) ceases temporarily or permanently to carry out the functions of an international depositary authority; or

(c) ceases for any reason to conduct its activities as an international depositary authority in an objective and impartial manner, subject to sub-paragraph (3), the applicant or proprietor may, unless the culture has been transferred to another international depositary authority which is able to make it available, make a new deposit of a culture of the micro-organism.

(2) For the purposes of paragraph 1 and this paragraph, the deposit shall be treated as always having been available if, within 3 months of the receipt of such notification or of the international depositary authority ceasing to perform the functions of an international depositary authority or to conduct its activities as such an authority in an objective and impartial manner, the applicant or proprietor –

(a) in a case where the deposit has not already been transferred, makes the new deposit;

(b) furnishes to the international depositary authority with which the new deposit is made a declaration that the culture so deposited is of the same microorganism as was the culture originally deposited; and



(c) requests amendment of the specification under section 31 or 38, as the case may be, so as to indicate the accession number of the transferred or new deposit and, where applicable, the name of the international depositary authority with which the deposit has been made.

(3) The new deposit referred to in sub-paragraph (1) –

(a) shall, subject to sub-paragraph (b), be made with the same international depositary authority as was the original deposit; or

(b) in the cases referred to in sub-paragraphs (1)(a)(ii), (b) and (c), shall be made with another international depositary authority which is able to satisfy the request.

### **Interpretation.**

5. In this Schedule –

"Budapest Treaty" means the Treaty on the International Recognition of the Deposit of Microorganisms for the purposes of Patent Procedure done at Budapest in 1977; "depositary institution" means an institution which, at all relevant times –

(a) carries out the functions of receiving, accepting and storing microorganisms and the furnishing of samples thereof; and

(b) conducts its affairs in so far as they relate to the carrying out of those functions in an objective and impartial manner;

"international depositary authority" means a depositary institution which has acquired the status of international depositary authority as provided in Article 7 of the Budapest Treaty.



## **FIFTH SCHEDULE**

### **REMUNERATION OF SCIENTIFIC ADVISERS**

1. A person appointed as a scientific adviser to assist the Registrar in proceedings under the Order and who attends the proceedings before the Registrar shall be paid –
  - (a) a reasonable amount for expenses incurred for transport between his usual place of residence and the place where the proceedings take place; and
  - (b) if the scientific adviser is required to be absent overnight from his usual place of residence, a reasonable amount as allowance for meals and accommodation up to a daily maximum of \$250.
2. A person appointed as a scientific adviser to assist the Registrar in proceedings under the Order shall, apart from the expenses and allowances referred to in paragraph 1, be paid an amount of not less than \$650 but not more than \$2,000 for each day or part thereof for which he hears the case or works on the report pursuant to an inquiry referred to him under rule 119(1)(b).
3. A person appointed as a scientific adviser to sit with the Registrar at the hearing of any proceedings may, apart from the expenses and allowances referred to in paragraph 1, be paid an amount not less than \$650 but not more than \$2,000 if he is subsequently not required to hear the proceedings with the Registrar.

\*\*\*\*\*



**REGISTRAR OF PATENT  
BRUNEI DARUSSALAM**

**PATENTS RULES [S 11/2013]**

**NEW PATENT APPLICATION**

[21]	<b>BN/N/2023/0071</b>	[22]	<b>06/07/2023</b>
[54]	<b>Fluidized Catalytic Conversion Method For Producing Low-Carbon Olefins From Hydrocarbons</b>		
[71]	<b>CHINA PETROLEUM &amp; CHEMICAL CORPORATION.</b> of 22 Chaoyangmen North Street, Chaoyang District, Beijing 100728, China <b>SINOPEC RESEARCH INSTITUTE OF PETROLEUM PROCESSING CO., LTD</b> of Zone 3, No. 18 Xueyuan Road, Haidian District, Beijing 100083, China		
[72]	1. ZUO, YANFEN 2. XU, YOUEAO 3. WANG, XIN 4. HE, MINGYUAN 5. SHA, YOUEIN 6. BAI, XUHUI		
[74]	<b>Messrs. HENRY GOH &amp; CO. SDN. BHD.</b> of AIP Law, Unit Nos. 405A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam.		
[31][32][33]	<b>No. 202110031551.4 Date: 11/01/2021 Country: China</b> <b>No. 202110245789.7 Date: 05/03/2021 Country: China</b> <b>No. 202110296896.2 Date: 19/03/2021 Country: China</b>		
[86]	<b>PCT/CN2021/101927</b>		
[87]	<b>WO/2022/147972</b>		
[51]	<b>C10G 69/00, C07C 1/20, C10G 11/02, C07C 11/04, C07C 11/06, C07C 4/06</b>		
[57]	<b>Disclosed is a fluidized catalytic conversion method for producing olefins from hydrocarbons, comprising conducting catalytic conversion of an olefin-rich feedstock in a first reaction zone of a fluidized catalytic conversion reactor, contacting a heavy feedstock with the reaction stream from the first reaction zone in a second reaction zone of the reactor for reaction, separating the effluent from the reactor, and recycling the resulting olefin-rich stream to the first reaction zone for further reaction. The method can improve the utilization rate of</b>		



**petrochemical resources and shows high yield and selectivity of ethylene, propylene and butylene.**




图 1

---

[21] BN/N/2023/0072 [22] 08/07/2023

[54] **Fluidized Catalytic Conversion Method For Maximizing Production Of Propylene**

[71] **CHINA PETROLEUM & CHEMICAL CORPORATION.** of 22 Chaoyangmen North Street, Chaoyang District, Beijing 100728, China  
**SINOPEC RESEARCH INSTITUTE OF PETROLEUM PROCESSING CO., LTD** of Zone 3, No. 18 Xueyuan Road, Haidian District, Beijing 100083, China

[72] 1. ZUO, YANFEN  
2. XU, YOUHAO  
3. SHU, XINGTIAN  
4. WANG, XIEQING  
5. LUO, YIBIN  
6. ZHANG, YUNPENG  
7. HAN, YUEYANG  
8. DU, LINGYIN

[74] Messrs. HENRY GOH & CO. SDN. BHD. of AIP Law, Unit Nos. 405A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam.

[31][32][33]  
No. 202110032113.X Date: 11/01/2021 Country: China  
No. 202110296904.3 Date: 19/03/2021 Country: China

[86] PCT/CN2021/101926

[87] WO/2022/147971

[51] C10G 11/00, C10G 11/05, C10G 11/18, C07C 11/06

[57] Disclosed a fluidized catalytic conversion method for maximizing the production of propylene, comprising the steps: 1) contacting a heavy feedstock oil with a catalytic conversion catalyst having a temperature of 650°C or higher for reaction; 2) contacting a hydrocarbon oil feedstock having an olefin content of 50 wt% or more with contact with the catalytic conversion catalyst after the reaction of step 1); 3) separating a first catalytic cracking distillate oil and a second catalytic cracking distillate oil from the reaction products; 4) separating an olefin-rich stream from the first catalytic cracking distillate oil; and 5) recycling the olefin-rich stream. The method can effectively improve the yield of propylene and realizes an effective utilization of petroleum resources.




图 1

---

[21] BN/N/2023/0073 [22] 10/07/2023

[54] **Chemical Fluid Containing An Antioxidant For Underground Treatment Of Oil And Gas Reservoirs**

[71] **NISSAN CHEMICAL CORPORATION** of 5-1, Nihonbashi 2-Chome Chuo-Ku, Tokyo 1036119, Japan  
**NISSAN CHEMICAL AMERICA CORPORATION** of 10333 Richmond Avenue, Suite 1100 Houston, Texas 77042, United States of America

[72] 1. OHORI, TAKAHIRO  
2. KITAGAWA, HIROTAKE  
3. MURAKAMI, SATORU  
4. MAGUIRE-BOYLE, SAMUEL  
5. SOUTHWELL, JOHN

[74] Messrs. SPRUSON & FERGUSON (ASIA) PTE LTD of AIP Law, Unit Nos. 404A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam.

[31][32][33]  
No. 17/146,047 Date: 11/01/2021 Country: United States of America

[86] PCT/US2022/011975



[87] WO/2022/150762

[51] C09K 8/00, C09K 8/03, E21B 43/00, E21B 43/16, E21B 43/20

[57] A chemical fluid for underground injection includes an inorganic substance, an antioxidant (e.g. ascorbic acid, gluconic acid, or a salt thereof, or  $\alpha$ -acetyl- $\gamma$ -butyrolactone, or bisulfite, or disulfite), and water. The inorganic substance may be a colloidal particle or a powder. The inorganic substance may be present in the chemical fluid in amounts of 0.001% by mass to 50% by mass based on the total mass of the chemical fluid for underground injection. The antioxidant may be present in the chemical fluid at a ratio of 0.0001 to 2 of the mass of the antioxidant to the mass of the inorganic substance. A surface of the inorganic substance may be coated with a silane compound. The chemical fluid may further include an anionic surfactant, a cationic surfactant, an amphoteric surfactant, a nonionic surfactant, or a mixture thereof.

---

[21] BN/N/2023/0074 [22] 17/07/2023

[54] **Methods Of Using A Gip/Glp1 Co-Agonist For Therapy**

[71] **ELI LILLY AND COMPANY** of Lilly Corporate Center, Indianapolis, Indiana 46285, United States of America

[72] 1. BENSON, CHARLES T.  
2. HAUPT, AXEL  
3. THOMAS, MELISSA KAY  
4. URVA, SHWETA

[74] Messrs. SPRUSON & FERGUSON (ASIA) PTE LTD of AIP Law, Unit Nos. 405A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam.

[31][32][33]  
No. 62/702/061 Date: 23/07/2018 Country: United States of America  
No. 62/730,565 Date: 13/09/2018 Country: United States of America  
No. 62/740,619 Date: 03/10/2018 Country: United States of America

[86] PCT/US2019/042817

[87] WO/2020/023382

[51] A61K 38/16, A61P 1/16, A61P 13/12, A61P 3/04, A61P 3/10, A61P 9/10

[57] The present invention provides a method for increasing glycemic control in a patient in need thereof, by administering tirzepatide, or a pharmaceutically



acceptable salt thereof. The present invention provides a method for improving weight management in a patient in need thereof, by administering tirzepatide, or a pharmaceutically acceptable salt thereof. Further providing a method for treating a condition selected from atherosclerosis, chronic kidney disease, NAFLD, and NASH. Further provided is a method to prevent or induce remission of diabetes comprising administration of tirzepatide, or a pharmaceutically acceptable salt thereof. Further provided is a dosing regimen for increasing glycemic control, improving weight management, and/or treating dyslipidemia.

---

[21] BN/N/2023/0075 [22] 20/07/2023

[54] **Materials And Methods For Monitoring Cancer By Administering An Anti-Mcl1 Antibody**

[71] **AMGEN INC.of One Amgen Center Drive Thousand Oaks, CA 91320-1799, United States of America**

[72] **1. KIELCZEWSKA, AGNIESZKA  
2. CHAN, BRIAN  
3. BOYLE, MICHAEL C.**

[74] **Messrs. SPRUSON & FERGUSON (ASIA) PTE LTD of AIP Law, Unit Nos. 405A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam.**

[31][32][33]  
No. 63/143,682 Date: 29/01/2021 Country: United States of America

[86] PCT/US2022/014401

[87] WO/2022/165240

[51] C07K 16/00, A61K 39/395

[57] **The disclosure provides anti-Mcl-1 antibodies of any form, and fragments thereof, that bind the antigen with unexpectedly high binding to Mcl-1, providing tools useful in methods of monitoring cancer cells expressing Mcl-1 and methods of treating cancers, particularly blood- borne cancers, comprising such cancer cells.**

---

[21] BN/N/2023/0076 [22] 20/07/2023

[54] **Pharmaceutical Composition Comprising A Diphenylpyrazine Derivative**

[71] **ACTELION PHARMACEUTICALS LTD. of Gewerbestrasse 16, Allschwil 4123,**



Switzerland

[72] 1. AMSSOMS, KATIE  
2. DE PROOST, EDDY  
3. DONG, WENYU  
4. HARTMAN KOK, PAUL  
5. HOLM, RENE  
6. KIMPE, KRISTOF  
7. MEURS, GREET  
8. VERSTRAETEN, MAXIM

[74] **Messrs. SPRUSON & FERGUSON (ASIA) PTE LTD of AIP Law, Unit Nos. 405A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam.**

[31][32][33]

No. PCT/EP2021/052208 Date: 29/01/2021 Country: European Patent Office

No. PCT/EP2021/082830 Date: 24/11/2021 Country: European Patent Office

[86] **PCT/EP2022/052073**

[87] **WO/2022/162158**

[51] **A61K 47/10, A61K 9/00, A61K 9/10, A61K 9/19, A61P 1/00**

[57] The present invention relates to a pharmaceutical composition comprising the calcium;{4- [(5,6-diphenylpyrazin-2-yl)(propan-2-yl)amino]butoxy}acetate, in particular to long-acting injectables comprising the same, the use of the pharmaceutical composition for the treatment or prevention of specific diseases, and a process to produce it.

---

[21] **BN/N/2023/0077** [22] **24/07/2023**

[54] **Rotary Vane, Rotating Device, And Power Generation Device**

[71] **ECO TECHNOLOGY CO., LTD. of 16-1, Hinooka-cho 1-chome, Chikusa-ku, Nagoya-shi, Aichi 464-0834, Japan**

[72] **1. KATO, MASAHIRO**

[74] **Messrs. AIP LAW of Unit Nos. 404A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam.**

[31][32][33]

No. 2021-012949 Date: 29/01/2021 Country: Japan


No. 2021-102908 Date: 22/06/2021 Country: Japan

[86] PCT/JP2021/039050

[87] WO/2022/163043

[51] F03D 3/06, F03D 9/32, B62D 35/00

[57] This wind power generation device comprises a plurality of rotary vanes 15 around a rotation axis. The rotary vanes 15 each have a front vane surface 16 curved so as to be parallel to the rotation axis and protrude forward in the rotation direction, and a rear vane surface 17 disposed on the back-surface side of the front vane surface 16, curved so as to be parallel to the rotation axis and protrude rearward in the rotation direction, and having a smaller curvature depth than the front vane surface 16. The front vane surface 16 has a first curved surface 19 that constitutes a portion separated from the rotation axis and that is formed facing forward in the rotation direction from an outside end part 21 of the rotary vane 15, and a second curved surface 20 that constitutes a portion near the rotation axis L1, that is formed facing rearward in the rotation direction from a vertex 18 of the front vane surface 16 so as to join into an inside end part 22, and that has a shorter surface length in plan view than the first curved surface 19. In the first curved surface 19, a recess 23 is formed in a position nearer the outside end part 21 than the vertex 18 of the front vane surface 16. Thus, a rotary vane is provided with which rotation efficiency can be improved in rotary vanes that rotate due to a fluid.



---

[21] BN/N/2023/0078 [22] 27/07/2023

[54] **Half-Life Extending Moieties And Methods Of Using The Same**

[71] **ELI LILLY AND COMPANY of LILLY CORPORATE CENTER, Indianapolis, Indiana 46285, United States of America**

[72] **1. FERRANTE, ANDREA  
2. HEUER, JOSEF GEORGE  
3. LEE, STACEY LYNN  
4. VERDINO, PETRA**



[74] **Messrs. SPRUSON & FERGUSON (ASIA) PTE LTD of AIP Law, Unit Nos. 405A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam.**

[31][32][33]

No. 63/144,696 Date: 02/02/2021 Country: United States of America

[86] **PCT/US2022/014728**

[87] **WO/2022/169757**

[51] **C07K 16/18, A61K 38/16**

[57] **The disclosure relates generally to biology and medicine, and more particularly it relates to compounds acting as half-life ( $t_{1/2}$ )-extending moieties for use with therapeutics, especially for improving  $t_{1/2}$  of biological-based therapeutics (i.e., biotherapeutics or biologics). The disclosure further relates to fusions and conjugates that include one or more of the compounds acting as  $t_{1/2}$ -extending moieties, as well as pharmaceutical compositions including the same and their use in treating various conditions, diseases or disorders.**

---

[21] **BN/N/2023/0079** [22] **29/07/2023**

[54] **Gitr Antagonists And Methods Of Using The Same**

[71] **ELI LILLY AND COMPANY of LILLY CORPORATE CENTER, Indianapolis, Indiana 46285, United States of America**

[72] **1. CAIN, PAUL FRANCIS  
2. LACERTE, MELINDA ANN  
3. LEE, STACEY LYNN  
4. VERDINO, PETRA  
5. WORTINGER, MARK ANDREW**

[74] **Messrs. SPRUSON & FERGUSON (ASIA) PTE LTD of AIP Law, Unit Nos. 405A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam.**

[31][32][33]

No. 63/144,696 Date: 02/02/2021 Country: United States of America

No. 63/297,968 Date: 10/01/2022 Country: United States of America

[86] **PCT/US2022/014752**



[87] WO/2022/169766

[51] C07K 14/765, C07K 16/18, C07K 16/28, A61K 39/395, A61P 37/06

[57] The present disclosure relates to compounds that bind to human GITR, pharmaceutical compositions comprising such compounds, and methods of using such compounds.

---

[21] BN/N/2023/0080 [22] 01/08/2023

[54] Methods Of Treating Cancer Using A Combination Of Serd Dosing Regimens

[71] ELI LILLY AND COMPANY of LILLY CORPORATE CENTER, Indianapolis, Indiana 46285, United States of America

[72] 1. BHAGWAT, SHRIPAD VENKATRAMAN  
2. HOLMAN, NATALIE STARR  
3. SALL, DANIEL JON  
4. SHAHDA, SAFI  
5. SMYTH, LILLIAN MARY  
6. SUZANNE REBECCA LOU  
7. YUEN, EUNICE SOEK MUN

[74] Messrs. SPRUSON & FERGUSON (ASIA) PTE LTD of AIP Law, Unit Nos. 405A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam.

[31][32][33]

No. 63/158,688 Date: 09/03/2021 Country: United States of America

No. 63/281,143 Date: 19/11/2021 Country: United States of America

[86] PCT/US2022/019274

[87] WO/2022/192203

[51] A61K 31/4196, A61K 31/436, A61K 31/4439, A61K 31/4741, A61K 31/506, A61K 31/5685

[57] Disclosed herein are dosing regimens for the administration of a compound of Formula I: (I) or pharmaceutically acceptable salt thereof to patients in need of such treatment. The dosing regimens include adjuvant therapy.



[21] BN/N/2023/0081 [22] 02/08/2023

[54] **Nanoemulsion Adjuvant Composition For Pneumococcal Conjugate Vaccines**

[71] **MERCK SHARP & DOHME LLC of 126 East Lincoln Avenue, Rahway, New Jersey 07065-0900, United States of America**

[72] **1. SMITH, WILLIAM, J.  
2. SOUKUP, RANDAL, J.  
3. SKINNER, JULIE, M.**

[74] **Messrs. SPRUSON & FERGUSON (ASIA) PTE LTD of AIP Law, Unit Nos. 405A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam.**

**No. 63/145,651 Date: 04/02/2021 Country: United States of America**

[86] PCT/US2022/014812

[87] WO/2022/169789

[51] A61K 39/09, A61K 39/385, A61K 39/39, A61P 11/00, A61P 31/04, A61P 37/04

[57] The present invention relates generally to the prevention of pneumococcal disease. More specifically, the invention relates to a composition comprising pneumococcal conjugates and a stable nanoemulsion (SNE).





FIG.4



[21]	<b>BN/N/2023/0082</b>	[22]	<b>08/08/2023</b>
[54]	<b>Methods Of Transporting Solid Formations Of Non-Volatile Bituminous Materials And Reducing Carbon Dioxide Emissions</b>		
[71]	<b>PHILERGOS GROUP FOUNDATION of 201-309 1 Street East, Cochrane, Alberta T4C 1Z3, Canada</b>		
[72]	<b>1. GIANNELIA, PAUL</b>		
[74]	<b>Messrs. AIP LAW of Unit Nos. 405A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam.</b>		
<b>[31][32][33]</b>			
<b>No. 17/665,532 Date: 05/02/2022 Country: United States of America</b>			
<b>No. 63/146,812 Date: 08/02/2021 Country: United States of America</b>			
[86]	<b>PCT/IB2022/051091</b>		
[87]	<b>WO/2022/168056</b>		
[51]	<b>C10C 3/14, B61D 3/16, B63B 25/00, B65D 88/74</b>		
[57]	<b>A method of transporting non-volatile bituminous materials from a first location to a second location involves carrying a plurality of irregular bricks formed by the bituminous material in transport chambers carried by vehicles. Bricks are defined by a plurality of non-planar surface, which create gaps between adjacent bricks, and can further include polymer skeletons and other features that help them float. The bricks can travel by land, sea, air, or rail and need not be heated while in transit. Transport chambers have active or preferably passive environmental control systems to circulate cooling air, water, or other substances through the chamber and the gaps between adjacent bricks. In a preferred embodiment, ambient air circulates among the bricks during travel by land and ambient water circulates among the bricks during marine travel. The vehicles carrying the transport chambers can be low-emissions or zero-emission vehicles including fuel-cell powered trains and ships.</b>		



FIG. 3A



---

[21] BN/N/2023/0083 [22] 08/08/2023

[54] **Solid Formations Of Non-Volatile Bituminous Materials Suitable For Reducing Carbon Dioxide Emissions During Transport**

[71] **PHILERGOS GROUP FOUNDATION** of 201-309 1 Street East, Cochrane, Alberta T4C 1Z3, Canada

[72] **1. GIANNELIA, PAUL**

[74] **Messrs. AIP LAW of Unit Nos. 405A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam.**

[31][32][33]  
**No. 17/665,520 Date: 05/02/2022 Country: United States of America**  
**No. 63/146,812 Date: 08/02/2021 Country: United States of America**


[86] PCT/IB2022/051093

[87] WO/2022/168058

[51] C10C 3/14


[57] **A method of transporting non-volatile bituminous materials from a first location to a second location involves carrying a plurality of irregular bricks formed by the bituminous material in transport chambers carried by vehicles. Bricks are defined by a plurality of non-planar surface, which create gaps between adjacent bricks, and can further include polymer skeletons and other features that help them float. The bricks can travel by land, sea, air, or rail and need not be heated while in transit. Transport chambers have active or preferably passive environmental control systems to circulate cooling air, water, or other substances through the chamber and the gaps between adjacent bricks. In a preferred embodiment, ambient air circulates among the bricks during travel by land and ambient water circulates among the bricks during marine travel. The vehicles carrying the**

transport chambers can be low-emissions or zero-emission vehicles including fuel-cell powered trains and ships.



[21]	BN/N/2023/0084	[22]	08/08/2023
[54]	<b>Methods Of Preparing Solid Formations Of Non-Volatile Bituminous Materials Suitable For Reducing Carbon Dioxide Emissions During Transport</b>		
[71]	<b>PHILERGOS GROUP FOUNDATION</b> of 201-309 1 Street East, Cochrane, Alberta T4C 1Z3, Canada		
[72]	<b>1. GIANNELIA, PAUL</b>		
[74]	<b>Messrs. AIP LAW</b> of Unit Nos. 405A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam.		
[31][32][33]	<b>No. 17/665,531 Date: 05/02/2022 Country: United States of America</b> <b>No. 63/146,812 Date: 08/02/2021 Country: United States of America</b>		
[86]	<b>PCT/IB2022/051094</b>		
[87]	<b>WO/2022/168059</b>		
[51]	<b>C08J 7/04, C08L 95/00, C10C 3/14, B29C 39/02</b>		
[57]	A method of preparing non-volatile bituminous material in solid form includes first accessing molds having mold cavities defining an irregularly shaped brick having a plurality of non-planar surfaces and preparing the bituminous material for casting by heating it until it is suitably viscous for casting and optionally blending it with an additive. Then, the molds can be filled with the bituminous materials, preferably using a retractable conduit that progressively fills each mold cavity from its bottom to its top. Next, the bituminous material in the molds is solidified until substantially solid bricks are formed. Optionally, a skeleton with optional additional buoyant features can be placed in each mold cavity prior to casting so that the resulting brick has increased buoyancy throughout, and the skeleton and any buoyant		

features can be customized according to the needs of the customer. The resulting bricks can be removed for transport.



---

[21] BN/N/2023/0085 [22] 08/08/2023

[54] **Receivers For Solid Formations Of Non-Volatile Bituminous Materials Suitable For Reducing Carbon Dioxide Emissions During Transport**

[71] **PHILERGOS GROUP FOUNDATION** of 201-309 1 Street East, Cochrane, Alberta T4C 1Z3, Canada

[72] **1. GIANNELIA, PAUL**

[74] **Messrs. AIP LAW** of Unit Nos. 405A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam.

[31][32][33]  
No. 17/665,531 Date: 05/02/2022 Country: United States of America  
No. 63/146,812 Date: 08/02/2021 Country: United States of America

[86] PCT/IB2022/051095


[87] WO/2022/168060

[51] C10C 3/10, C10C 3/12, C10C 3/14

[57] A receiver for irregularly shaped bricks cast from non-volatile bituminous material includes a receiver with a specialized storage chamber that can receive viscous bituminous material and a concave lid preferably modified with a radiant heating system that can accept and melt or soften arriving bricks. The lid includes multiple openings or other delivery routes that funnel the melted bituminous material to the chamber below. The radiant heating system can be electrical where cables or grids are embedded in the lid or where conductive materials coat or are distributed throughout the lid. Alternatively, the radiant heating system can be hydronic where



channels or conduits are embedded in the lid to circulate heated liquid such as water or water mixed with propylene glycol. The receiver can also include blenders, skimmers, and additional heaters to further skim, blend, or process the bituminous material collected in the chamber.



---

[21] BN/N/2023/0086 [22] 14/08/2023

[54] **LONG-ACTING AMYLIN RECEPTOR AGONISTS AND USES THEREOF**

[71] **ELI LILLY AND COMPANY of LILLY CORPORATE CENTER, Indianapolis, Indiana 46285, United States of America**

[72] **1. ABRAHAM, Milata Mary  
2. BRIERE, Daniel Anthony  
3. GUO, Lili  
4. KEYSER, Samantha Grace Lyons  
5. LEE, John  
6. QU, Hongchang**

[74] **Messrs. SPRUSON & FERGUSON (ASIA) PTE LTD of AIP Law, Unit Nos. 405A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam.**

[31][32][33]  
**No. 63/155,894 Date: 03/03/2021 Country: United States of America**

[86] **PCT/US2022/018434**

[87] **WO/2022/187305**

[51] **C07K 14/605, A61K 38/00, A61K 38/17, A61K 38/22, A61P 3/10**

[57] **The present disclosure relates to the field of medicine. More particularly, the disclosure is in the field of treatment of diabetes, obesity and/or chronic weight management, dyslipidemia and/or NASH. The disclosure relates to compounds that**



agonize the amylin receptor and can lower food intake, body weight, glucose and/or triglycerides, so can be used to treat diabetes, obesity, and/or dyslipidemia. The present disclosure also includes pharmaceutical compositions containing such compounds and therapeutic uses of such compounds and compositions.

---

[21] BN/N/2023/0087 [22] 17/08/2023

[54] **Fgfr3 Inhibitor Compounds**

[71] **ELI LILLY AND COMPANY of LILLY CORPORATE CENTER, Indianapolis, Indiana 46285, United States of America**

[72] **1. ABRAHAM, ADEDOYIN DAVID  
2. BUME, DESTA DORO  
3. CONDROSKI, KEVIN RONALD  
4. DILGER, ANDREW KARL  
5. HAZLITT, ROBERT ALAN  
6. KERCHER, TIMOTHY SCOTT  
7. METCALFF, ANDREW TERRANCE  
8. URKALAN, KAVERI BALAN  
9. WALLS, SHANE MICHAEL**

[74] **Messrs. SPRUSON & FERGUSON (ASIA) PTE LTD of AIP Law, Unit Nos. 405A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam.**


[31][32][33]  
No. 63/156,527 Date: 04/03/2021 Country: United States of America

[86] **PCT/US2022/018644**

[87] **WO/2022/187443**

[51] **C07D 471/04, A61P 35/00**

[57] **The present invention provides compounds of the formula:, for use in the treatment of systemic sclerosis, fibrosis (e.g. pulmonary fibrosis), achondroplasia, thanatophoric dysplasia (e.g. type I), severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN), muenke syndrome or cancer.**



---

[21] BN/N/2023/0088 [22] 17/08/2023

[54] **Anti-Cd30l Antibodies And Uses Thereof**

[71] **PROMETHEUS BIOSCIENCES, INC.** of 3050 Science Park Road, San Diego, California 92121, United States of America  
**DR. FALK PHARMA GMBH** of Leinenweberstraße 5, 79108 Freiburg im, Breisgau, Germany

[72] 1. FECTEAU, JESSIE-FARAH  
2. RENSHAW, MARK  
3. FRANSSON, JOHAN  
4. LAURENT, OLIVIER  
5. BARNETT, BURTON

[74] **Messrs. SPRUSON & FERGUSON (ASIA) PTE LTD** of AIP Law, Unit Nos. 405A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam.


[31][32][33]  
No. 63/150,373 Date: 17/02/2021 Country: United States of America

[86] PCT/US2022/016565

[87] WO/2022/177963

[51] C07K 16/24, C07K 16/28, A61K 39/395, A61P 1/00, A61P 29/00

[57] **Described herein are anti-CD30L antibodies and pharmaceutical compositions for the treatment of autoimmune diseases and disorders such inflammatory bowel disease (IBD), including Crohn's Disease (CD) and ulcerative colitis (UC).**



[21] BN/N/2023/0089

[22]

17/08/2023

[54] Compositions Comprising Humanized Antibodies To Tnf-Like Ligand 1a (Tl1a) And Uses Thereof

[71] PROMETHEUS BIOSCIENCES, INC. of 3050 Science Park Road, San Diego, California 92121, United States of America  
CEDARS-SINAI MEDICAL CENTER of 8700 Beverly Blvd. Los Angeles, California 90048, United States of America

[72] 1. LUO, ALLISON  
2. OTSUKI, LAUREN  
3. MANNING, MARK  
4. LAURENT, OLIVIER  
5. BILSBOROUGH, JANINE  
6. HENKLE, BRADLEY  
7. TARGAN, STEPHAN R.

[74] Messrs. SPRUSON & FERGUSON (ASIA) PTE LTD of AIP Law, Unit Nos. 405A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam.


[31][32][33]  
No. 63/150,825 Date: 18/02/2021 Country: United States of America  
No. 63/180,892 Date: 28/04/2021 Country: United States of America  
No. 63/226,037 Date: 27/07/2021 Country: United States of America  
No. 63/285,781 Date: 03/12/2021 Country: United States of America

[86] PCT/US2022/016841

[87] WO/2022/178159

[51] C07K 16/24, A61K 39/395, A61P 1/04

[57] Described herein are anti-CD30L antibodies and pharmaceutical compositions for the treatment of autoimmune diseases and disorders such inflammatory bowel disease (IBD), including Crohn's Disease (CD) and ulcerative colitis (UC).



[21] BN/N/2023/0090 [22] 19/08/2023

## [54] Aquaculture Feed Composition Comprising Charcoal

[71] NUTRECO IP ASSETS B.V. of Veerstraat 38, NL-5831 JN Boxmeer, Netherlands  
SKRETTING AQUACULTURE RESEARCH CENTRE AS of Postboks 48, 4001  
Stavanger, Norway

[72] 1. DHERT, PHILIPPE  
2. CHUA, SEONG-CHEA  
3. ROSENLUCK, GRETHER

[74] Messrs. HENRY GOH & CO. SDN. BHD. of AIP Law, Unit Nos. 405A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam.

[31][32][33]  
No. 21159371.0 Date: 25/02/2021 Country: European Patent Office  
No. 21198080.0 Date: 21/09/2021 Country: European Patent Office

[86] PCT/NO2022/050052

[87] WO/2022/182248

[51]  $\Delta^{23}\text{K}$  10/37,  $\Delta^{23}\text{K}$  20/147,  $\Delta^{23}\text{K}$  40/10,  $\Delta^{23}\text{K}$  40/25,  $\Delta^{23}\text{K}$  40/39,  $\Delta^{23}\text{K}$  50/80

[57] The invention relates to the field of aquaculture feed compositions and to the field of feeding and farming of aquatic organisms including fish, such as seabream and

crusta-ceans, so as shrimp. Provided is an aquaculture feed composition in the form of pellets having specific dimensions and comprising high wt.% of protein and comprising a source of charcoal. Results show the aquaculture feed compositions having different benefits over prior art aquaculture feed compositions.




Fig. 1

---

[21] BN/N/2023/0091 [22] 21/08/2023

[54] **Heterocyclic Rip1 Kinase Inhibitors**

[71] **RIGEL PHARMACEUTICALS, INC. of 1180 Veterans Boulevard, South San Francisco, California 94080, United States of America**

[72] **1. BHAMIDIPATI, SOMASEKHAR  
2. DEFREES, KYLE  
3. SHAW, SIMON  
4. TAYLOR, VANESSA**

[74] **Messrs. SPRUSON & FERGUSON (ASIA) PTE LTD of AIP Law, Unit Nos. 405A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam.**


[31][32][33]  
No. 63/159,970 Date: 11/03/2021 Country: United States of America

[86] PCT/US2022/019744

[87] WO/2022/192533

[51] A61P 11/00, A61P 17/00, A61P 19/00, A61P 35/00, A61P 37/00, A61P 5/00

[57] Disclosed herein are kinase inhibitory compounds, such as a receptor- $\alpha$  interacting protein-1 (RIP1) kinase inhibitor compounds of formula (I), as well as pharmaceutical compositions and combinations comprising such inhibitory compounds. The disclosed compounds, pharmaceutical compositions, and/or combinations may be used to treat or prevent a kinase-associated disease or condition, particularly a RIP 1-associated disease or condition.



Formula I

---

[21] BN/N/2023/0092 [22] 21/08/2023

[54] **Incretin Analog-Containing Compositions And Uses Thereof**

[71] **ELI LILLY AND COMPANY** of Lilly Corporate Center, Indianapolis, Indiana 46285, United States of America

[72] **1. GOPALRATHNAM, GANAPATHY  
2. MINIE, CHRISTOPHER SEARS**

[74] **Messrs. SPRUSON & FERGUSON (ASIA) PTE LTD** of AIP Law, Unit Nos. 405A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam.

[31][32][33]  
No. 63/164,702 Date: 23/03/2021 Country: United States of America

[86] PCT/US2022/021309

[87] WO/2022/204117

[51] A61K 38/00, A61K 47/10, A61K 47/26, A61K 9/00, A61P 3/10

[57] A composition is provided that includes an incretin analog having activity at each the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon (GCG) receptors (*i.e.*, tri-receptor agonist) and one or more additional agents such as a tonicity agent and a preservative. Methods also are provided for treating diseases such as type 2 diabetes mellitus, dyslipidemia, metabolic syndrome, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis



and obesity with the composition.

---

[21] BN/N/2023/0093 [22] 21/08/2023

[54] Glucocorticoid Receptor Agonists

[71] ELI LILLY AND COMPANY of Lilly Corporate Center, Indianapolis, Indiana 46285, United States of America

[72] 1. AHMED, ADEL AHMED RASHAD  
2. CLAYTON, JOSHUA RYAN  
3. LOPEZ, JOSE EDUARDO  
4. MCMILLEN, WILLIAM THOMAS  
5. STITES, RYAN EDWARD  
6. WILSON, TAKAKO  
7. WURST, JACQUELINE MARY

[74] Messrs. SPRUSON & FERGUSON (ASIA) PTE LTD of AIP Law, Unit Nos. 405A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam.


[31][32][33]  
No. 63/164,613 Date: 23/03/2021 Country: United States of America  
No. 63/260,451 Date: 20/08/2021 Country: United States of America

[86] PCT/US2022/021299

[87] WO/2022/204108

[51] C07J 71/00, A61P 17/00, A61P 19/02

[57] A composition is provided that includes an incretin analog having activity at each the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon (GCG) receptors (*i.e.*, tri-receptor agonist) and one or more additional agents such as a tonicity agent and a preservative. Methods also are provided for treating diseases such as type 2 diabetes mellitus, dyslipidemia, metabolic syndrome, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis and obesity with the composition.



---

[21] BN/N/2023/0094 [22] 23/08/2023

[54] **Vmat2 Inhibitors And Methods Of Use**

[71] **NEUROCRINE BIOSCIENCES, INC.** of 12780 El Camino Real San Diego, California 92130, United States of America

[72] 1. HARRIOTT, NICOLE  
2. PAGANO, NICHOLAS  
3. BOON, BYRON A

[74] Messrs. SPRUSON & FERGUSON (ASIA) PTE LTD of AIP Law, Unit Nos. 405A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam.


[31][32][33]  
No. 63/164,135 Date: 22/03/2021 Country: United States of America

[86] PCT/US2022/021080

[87] WO/2022/203984

[51] C07D 471/04, A61K 31/4745, A61P 25/00

[57] This disclosure relates generally to VMAT2 inhibitor compounds of formula (I), compositions, and methods related thereto.



[21]	BN/N/2023/0095	[22]	29/08/2023
[54]	Cutting Apparatus		
[71]	DECOM ENGINEERING of 55 Mullan Rd Cookstown Tyrone BT80 0JE, United Kingdom		
[72]	1. CONWAY, GREG 2. CONWAY, SEAN		
[74]	Messrs. MIRANDAH ASIA (SINGAPORE) PTE LTD, of AIP Law, Unit Nos. 405A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam.		


[31][32][33]  
No. 2102708.1 Date: 25/02/2021 Country: United Kingdom

[86] PCT/EP2022/054897

[87] WO/2022/180258

[51] B23D 57/00

[57] Cutting Apparatus A cutting apparatus (1) configured for subsea application. The cutting apparatus (1) has a cutting means drive arrangement (100) having at least one cutting means (12) and at least one motive means (43) for providing power to the cutting means (12). The cutting apparatus (1) is configured such that all, some or a part of the cutting means drive arrangement (100) is interchangeable, on site. This enables use of a single cutting apparatus to perform a variety of different cuts and/or to cut a variety of different objects.



[21] BN/N/2023/0096 [22] 31/08/2023



[54] **Use Of Luvadaxistat For The Treatment Of Cognitive Impairment**

[71] **TAKEDA PHARMACEUTICAL COMPANY LIMITED** of 1-1, Doshomachi 4-chome, Chuo-ku, Osaka-shi, Osaka 541-0045, Japan  
**NEUROCRINE BIOSCIENCES, INC.** of 12780 El Camino Real San Diego, California 92130, United States of America

[72] 1. PATHI JAGANNATHAM, NAGA VENKATESHA MURTHY  
2. HAREL, BRIAN  
3. DEMARTINIS, NICHOLAS  
4. DUNAYEVICH, EDUARDO  
5. O'DONNELL, PATRICIO  
6. MACEK, THOMAS A.  
7. BRAR, SATJIT SINGH  
8. FUREY, MAURA  
9. GE, TINGTING  
10. SINGH, JASKARAN B.

[74] Messrs. SPRUSON & FERGUSON (ASIA) PTE LTD of AIP Law, Unit Nos. 405A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam.


[31][32][33]  
No. 63/200,327 Date: 01/03/2021 Country: United States of America  
No. 63/229,945 Date: 05/08/2021 Country: United States of America  
No. 63/264,747 Date: 01/12/2021 Country: United States of America  
No. 63/265,628 Date: 17/12/2021 Country: United States of America

[86] PCT/US2022/018112

[87] WO/2022/187127

[51] A61K 31/496, A61K 31/50, A61K 31/519, A61K 31/554, A61K 45/06, A61P 25/18

[57] Methods of treating at least one cognitive symptom, *e.g.*, at least one cognitive symptom associated with schizophrenia, comprising administering at least one compound chosen from Compound (I) and pharmaceutically acceptable salts thereof are disclosed. Also disclosed are methods of increasing D-serine levels, synaptic plasticity, and/or long-term potentiation comprising administering at least one compound chosen from Compound (I) and pharmaceutically acceptable salts thereof.



---

[21] BN/N/2023/0097 [22] 02/09/2023

[54] **Amino Acid Compounds And Methods Of Use**

[71] **PLIANT THERAPEUTICS, INC. of 260 Littlefield Avenue, South San Francisco, California 94080, United States of America**

[72] 1. CHA, JACOB  
2. DONG, CHENGGUO  
3. HOM, TIMOTHY  
4. JIANG, LAN  
5. LEFTHERIS, KATERINA  
6. LI, HUI  
7. MORGANS JR., DAVID J.  
8. MUÑOZ, MANUEL  
9. REILLY, MAUREEN  
10. ZHENG, YAJUN

[74] **Messrs. SPRUSON & FERGUSON (ASIA) PTE LTD of AIP Law, Unit Nos. 405A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam.**

[31][32][33]  
**No. US62/639,988 Date: 07/03/2018 Country: United States of America**  
**No. US62/690,933 Date: 27/06/2018 Country: United States of America**

[86] PCT/US2019/021243


[87] WO/2019/173653

[51] C07D 401/12, A61K 31/4375

[57] The invention relates to compounds of formula (A) and formula (I): or a salt thereof, wherein R<sup>1</sup>, R<sup>2</sup>, R<sup>10</sup>, R<sup>11</sup>, R<sup>12</sup>, R<sup>13</sup>, R<sup>14</sup>, R<sup>15</sup>, R<sup>16</sup>, q and p are as described herein. Compounds of formula (A), formula (I), and pharmaceutical compositions



thereof are  $\alpha\beta\delta$  integrin inhibitors that are useful for treating fibrosis such as idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP).



---

[21] BN/N/2023/0098 [22] 02/09/2023

[54] **Rip1 Inhibitory Compounds And Methods For Making And Using The Same**

[71] **RIGEL PHARMACEUTICALS, INC.** of 1180 Veterans Boulevard, South San Francisco, California 94080, United States of America

[72] 1. CHEN, YAN  
2. YU, JIAXIN  
3. SHAW, SIMON  
4. DARWISH, IHAB  
5. TAYLOR, VANESSA  
6. BHAMIDIPATI, SOMASEKHAR  
7. KOLLURI, RAO

[74] Messrs. SPRUSON & FERGUSON (ASIA) PTE LTD of AIP Law, Unit Nos. 405A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam.

[31][32][33]  
No. US62/897,223 Date: 06/09/2019 Country: United States of America  
No. US62/932,404 Date: 07/11/2019 Country: United States of America  
No. US63/001,016 Date: 27/03/2020 Country: United States of America  
No. US63/004,290 Date: 02/04/2020 Country: United States of America  
No. US63/004,301 Date: 02/04/2020 Country: United States of America  
No. US63/004,319 Date: 02/04/2020 Country: United States of America

[86] PCT/US2020/049487

[87] WO/2021/046407

[51] C07D 413/12, C07D 413/14, A61K 31/553, A61P 37/00

[57] Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting



protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds. The disclosed compounds, pharmaceutical compositions, and/or combinations may be used to treat or prevent a kinase-associated disease or condition, particularly a RIP1-associated disease or condition.

---

[21] BN/N/2023/0099 [22] 09/09/2023

[54] **Alpha V Beta 6 And Alpha V Beta 1 Integrin Inhibitors And Uses Thereof**

[71] **DICE MOLECULES SV, INC. of 279 E. Grand Avenue, Suite 300, South San Francisco, California 94080, United States of America**

[72] **1. SHARMA, LALIT KUMAR  
2. FATHEREE, PAUL ROSS  
3. JACOBSEN, JOHN R.**

[74] **Messrs. SPRUSON & FERGUSON (ASIA) PTE LTD of AIP Law, Unit Nos. 405A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam.**

[31][32][33]  
No. US63/159,063 Date: 10/03/2021 Country: United States of America

[86] **PCT/US2022/019759**

[87] **WO/2022/192545**

[51] **C07D 471/04, C07D 491/18, C07D 495/04, A61P 11/00, A61P 13/12, A61P 35/00**

[57] **Provided herein are alpha V beta 6 and alpha V beta 1 integrin inhibitors, methods of making such alpha V beta 6 and alpha V beta 1 integrin inhibitors, pharmaceutical compositions of alpha V beta 6 and alpha V beta 1 integrin inhibitors, and methods of treating and/or preventing various medical disorders in a subject by administering to the subject in need thereof alpha V beta 6 and alpha V beta 1 integrin inhibitors.**




FIG. 1



---

[21] BN/N/2023/0100 [22] 12/09/2023

[54] **Pro Drugs Of Pde10 Compounds**

[71] **MERCK SHARP & DOHME LLC. of 126 East Lincoln Avenue, Rahway, New Jersey 07065, United States of America**

[72] **1. MITTAL, SACHIN  
2. SKUDLAREK, JASON, W.  
3. RAHEEM, IZZAT, T.**

[74] **Messrs. SPRUSON & FERGUSON (ASIA) PTE LTD of AIP Law, Unit Nos. 405A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam.**

[31][32][33]  
No. US63/162,333 Date: 17/03/2021 Country: United States of America

[86] **PCT/US2022/020297**

[87] **WO/2022/197647**

[51] **C07D 417/14, A61K 31/506, A61P 25/18**

[57] **The present invention is directed to pro drugs of 2-methyl-N-((5-methyl-1,3,4-thiadiazol-2-yl)methyl)-6-(((1S,2S)-2-(5-methylpyridin-2-yl)cyclopropyl)methoxy)pyrimidin-4-amine which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.**

---

[21] BN/N/2023/0101 [22] 14/09/2023

[54] **Sotorasib Dosing Regimen**

[71] **AMGEN INC. of One Amgen Center Drive Thousand Oaks, California 91320-1799, United States of America**

[72] **1. SHARMA, LALIT KUMAR  
2. HENARY, HABY  
3. HOUK, BRETT E.**

4. MATHER, OMAR A.  
5. NGARMCHAMNANRITH, GATAREE  
6. DUTTA, SANDEEP

[74] Messrs. SPRUSON & FERGUSON (ASIA) PTE LTD of AIP Law, Unit Nos. 405A-410A, 4th Floor, Wisma Jaya, Jalan Pemancha, Bandar Seri Begawan BS8811, Brunei Darussalam.

[31][32][33]

No. US63/162,273 Date: 17/03/2021 Country: United States of America

No. US63/185,054 Date: 06/05/2021 Country: United States of America

No. US63/190,096 Date: 18/05/2021 Country: United States of America


[86] PCT/US2022/020642

[87] WO/2022/197865

[51] A61K 31/519, A61P 35/00

[57] Provided herein are methods of administering a 240 mg total daily dose of sotorasib to a patient suffering from a cancer having a *KRAS G12C* mutation. Also provided herein are methods of treating *KRAS G12C* mutated cancer in a patient comprising administering a total daily dose of 960 mg sotorasib to the patient, and reducing the total daily dose of sotorasib to 480 mg in a patient experiencing an adverse event to the 960 mg dose of sotorasib.

FIG. 1





## REGISTRAR OF PATENT

### BRUNEI DARUSSALAM

**PATENTS RULES [S 11/2013]**

#### **PATENT GRANTED UNDER SECTION 30**

---

**Application No.:** BN/N/2018/0004  
**Date of Grant:** 19 September, 2023  
**Applicant(s) / Proprietor(s):** NIPPON STEEL & SUMITOMO METAL  
VALLOUREC OIL AND GAS FRANCE  
**Title of Invention:** Threaded Connection For Steel Pipes

---

**Application No.:** BN/N/2019/0111  
**Date of Grant:** 4 September, 2023  
**Applicant(s) / Proprietor(s):** AMGEN INC.  
**Title of Invention:** Compounds That Inhibit Mcl-1 Protein

---

**Application No.:** BN/N/2020/0069  
**Date of Grant:** 4 September, 2023  
**Applicant(s) / Proprietor(s):** AMGEN INC.  
**Title of Invention:** Improved Elevated Structure-Mounted Lighting System

---

**Application No.:** BN/N/2020/0093  
**Date of Grant:** 4 September, 2023  
**Applicant(s) / Proprietor(s):** RIGEL PHARMACEUTICALS, INC.  
**Title of Invention:** Rip1 Inhibitory Compounds And Methods For Making And  
Using The Same

---



---

**Application No.:** BN/N/2020/0095  
**Date of Grant:** 4 September, 2023  
**Applicant(s) / Proprietor(s):** NIPPON SHINYAKU CO., LTD.  
**Title of Invention:** Azabenzimidazole Compounds And Pharmaceutical

---

**Application No.:** BN/N/2020/0100  
**Date of Grant:** 4 September, 2023  
**Applicant(s) / Proprietor(s):** SHELL INTERNATIONALE RESEARCH MAATSCHAPPIJ B.V.  
**Title of Invention:** Synthetic Modeling With Noise Simulation

---

**Application No.:** BN/N/2020/0101  
**Date of Grant:** 4 September, 2023  
**Applicant(s) / Proprietor(s):** SHELL INTERNATIONALE RESEARCH MAATSCHAPPIJ B.V.  
**Title of Invention:** Synthetic Modeling

---